Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers

Pharmacology

Volumn 82, Issue 3, 2008, Pages 221-227

  Xu, Ping ^a   Jiang, Zhi Ping ^b   Zhang, Bi Kui ^a   Tu, Ji Ying ^a   Li, Huan De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Digoxin; MDR1 haplotype; P glycoprotein; Single nucleotide polymorphism

Indexed keywords

DIGOXIN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CHINESE; DRUG ABSORPTION; DRUG FORMULATION; FEMALE; GENE; GENE FREQUENCY; GENETIC LINKAGE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MDR1 GENE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALLELES; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOTONIC AGENTS; CHINA; DIGOXIN; EXONS; FEMALE; HAPLOTYPES; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 52049100135     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156488     Document Type: Article

References (27)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-398.
2. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987;77:142-144.
3. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brochmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
4. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54:610-616.
5. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
6. Balram C, Sharma A, Sivathasan C, Lee EJ: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmcol 2003;56:78-83.
7. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18:1400-1404.
8. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Dubert L, Jaillon P, Func-Brentano C, Trugnan G, Becquemont L: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003;58:809-812.
9. Zhang WX, Chen GL, Zhang W, Tan ZR, Liu J, Zhou G, Hu DL, Zhou HH: MDR1 genotypes do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin Chim Acta 2005;359:46-52.
10. Chowbay B, Li H, David M, Cheung YB, Lee EJ: Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005;60:159-171.
11. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmoller J, Cascorbi I, Roots I: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002;72:584-594.
12. Kurzawski M, Bartnicka L, Florczak M, Górnik W, Droździk M: Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep 2007;59:107-111.
13. Mai I, Störmer E, Goldammer M, Johne A, Krüger H, Budde K, Roots I: MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003;43:1101-1107.
14. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003;13:89-95.
15. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, Roots I: MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004;58:548-553.
16. Kim KA, Park PW, Park JY: Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007;63:53-58.
17. Anglicheau D, Thervet E, Etienne I, Hurault de Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004;75:422-433.
18. Chiou WL, Chung SM, Wu TC, Ma C: A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001;39:93-101.
19. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12:437-450.
20. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ: Multidrug resistance gene G1199A polymorphism alters efflux transport activity of Pglycoprotein. J Pharmacol Exp Ther 2004;310:1199-1207.
21. Zhang WX, Chen B, Zhang W, Chen N, Yu ZC, Cai WM: Effect of MDR1 gene polymorphism on progression of end-stage renal disease. Acta Pharmacol Sin 2007;28:579-583.
22. Garton T: Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus 1. Transplantation 2002;74:745.
23. Bailey DG, Dresser GK: Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-297.
24. Goto M, Masuda S, Saito H, Uemoto S, Kluchi T, Tanaka K, Inui K: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics 2002;12:451-457.
25. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-528.
26. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB: Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
27. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-533.